By Adam Clark

 

GlaxoSmithKline PLC said Tuesday that it and South Korean company SK Bioscience Co Ltd. have started a Phase 3 trial of their Covid-19 vaccine combination.

The British pharmaceutical company said the advance follows positive immunogenicity and safety data from earlier trials and that the partners are aiming for a global supply of the vaccine via the Covax facility in the first half of 2022, subject to data and regulatory review.

The trial combines SK Bioscience's vaccine candidate with GSK's adjuvant, an ingredient used to prompt a stronger immune response.

The randomized trial will enroll around 4,000 participants and compare the vaccine against the AstraZeneca PLC vaccine, with data due in the first half of 2022.

 

Write to Adam Clark at adam.clark@wsj.com

 

(END) Dow Jones Newswires

August 31, 2021 02:35 ET (06:35 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni Glaxosmithkline (LSE:GSK)
Storico
Da Set 2021 a Ott 2021 Clicca qui per i Grafici di Glaxosmithkline
Grafico Azioni Glaxosmithkline (LSE:GSK)
Storico
Da Ott 2020 a Ott 2021 Clicca qui per i Grafici di Glaxosmithkline